Foreign investors' KOSDAQ 2 trillion 5,000 billion net purchases; individual stocks surge on biotech and AI clinical news
Foreign investors 5 month 22 day made net purchases of KOSDAQ stocks worth 2 trillion 5,000 billion. Buying was concentrated in semiconductors, robotics and biotech. GI Innovation's shares rose after the release of ASCO abstracts and the announcement of the ORR for its kidney cancer drug at 40%, while D&D Pharmatech gained 14%.
5 month 22 day, foreign investors made net purchases of KOSDAQ stocks worth 2 trillion 5,000 billion. Buying flowed mainly into the semiconductor, robotics and biotech sectors. The day's top net purchases were concentrated in those sectors.
Active pharmaceutical ingredient companies are seeing the effects of expanding their factories. The expansion has been accompanied by more orders and improved earnings. Some companies said the expansions had increased production and shipments.
D&D Pharmatech's shares rose 14% on expectations for clinical results related to the European Association for the Study of the Liver. Investor interest grew around the release of the clinical results. The company disclosed the progress of the clinical program related to its conference presentation.
GI Innovation’s share price 23% surged. The company announced that its immuno-oncology drug showed an objective response rate (ORR) of 40%. The announcement presented this as a key figure from the clinical results.
Korean-American biotech company Ingenia Therapeutics received preliminary approval for its listing review. The company has entered a stage where it can move ahead in earnest with the listing process. The company will announce its future disclosure schedule separately.
During the same period, biotech stocks posted mixed moves depending on individual clinical results and listing-related announcements. Some stocks recorded gains in the double digits. Investors reviewed each company’s disclosures and clinical details.